Skip to main content

Table 1 Patient demographics and baseline tumour characteristics

From: Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer

 

Chemotherapy group (n = 87)

Endocrine therapy group (n = 87)

p value

Age group at baseline(years)

 Mean (SD)

42.5 ± 5.6

41.5 ± 5.8

0.255

 20–29

2 (2.3%)

2 (2.3%)

 

 30–39

20 (23.0%)

31 (35.6%)

 

 40–49

59 (69.0%)

50 (59.8%)

 

 50–55

6 (5.7%)

4 (2.3%)

 

BMI (kg/m2)

  

0.921

 < 18.5

5 (5.7%)

4 (4.6%)

 

 18.5–24.9

54 (62.1%)

56 (64.4%)

 

 25–29.9

24 (27.6%)

20 (23.0%)

 

 ≥ 30

4 (4.6%)

7 (8.0%)

 

Clinical T stage

  

0.746

 T1

13 (14.9%)

9 (10.3%)

 

 T2

58 (66.7%)

62 (71.3%)

 

 T3

16 (18.4%)

16 (18.4%)

 

Clinical N stage

  

0.808

 N1

78 (89.7%)

76 (87.4%)

 

 N2

5 (5.7%)

5 (5.7%)

 

 N3

4 (4.6%)

6 (6.9%)

 

Grade

  

0.616

 G1/2

52 (59.8%)

61 (70.1%)

 

 G3

3 (3.4%)

4 (4.6%)

 

 NA

32 (36.8%)

22 (25.3%)

 

Ki-67 expression (%)

  

0.891

 ≤ 20%

49 (56.3%)

48 (55.2%)

 

 > 20%

36 (41.4%)

37 (42.6%)

 

 Unknown

2 (2.3%)

2 (2.3%)

 

Planned operation

  

0.141

 Mastectomy

45 (51.7%)

53 (60.6%)

 

 Breast-conserving surgery

42 (48.3%)

34 (39.1%)

 
  1. Data are n (%), unless otherwise stated
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us